Eleven Therapeutics, a biotechnology company developing next-gen RNA therapeutics combining chemistry and artificial intelligence, entered a research collaboration with Novo Nordisk to identify novel molecules that promote precise delivery of nucleic acid leveraging Eleven’s DELiveri platform, to usher in a new era of medicines for cardiometabolic diseases. Nucleic acid therapeutics have immense potential for cardiometabolic diseases. However, the major challenge to successful developme...